Vnitr Lek 2021, 67(6):372-377 | DOI: 10.36290/vnl.2021.096

Aktuální témata kardiovaskulární prevence

MUDr. Zuzana Zafarová
Praha

I přes pokroky medicíny v oblasti kardiovaskulárního (KV) zdraví tráví Češi mnoho let svého života s KV onemocněním. Českým ženám patřilo v roce 2016 z hlediska tohoto parametru druhé nejhorší místo v Evropě, českým mužům 6. nejhorší místo (Obr. 1) (1). Při střední délce života 81,9 roku tráví české ženy 20 let svého života s KV onemocněním, u mužů při střední délce života 76,1 roku představuje čas strávený s onemocněním 15 let. Spolu se stárnutím populace znamená tento fakt obrovské ekonomické náklady, zátěž pro zdravotní systém a snížení kvality života pacientů. Pojďme se na ilustračním příkladu pacienta zamyslet nad tím, proč je stav české populace z tohoto pohledu tak nepříznivý a jak lze tuto situaci změnit.

Published: October 13, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zafarová Z. Aktuální témata kardiovaskulární prevence. Vnitr Lek. 2021;67(6):372-377. doi: 10.36290/vnl.2021.096.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10; 3 92(10159): 1789-1858.
    2. Ettehad D, Emdin CA, Kiran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016 Mar 5; 387(10022): 957-967. Go to original source... Go to PubMed...
    3. Ference BA, Bhatt DL, Catapano AL et al. Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA. 2019 Oct 8; 322(14): 1381-1391. Go to original source... Go to PubMed...
    4. Böhm M, Schumacher H, Teo KK et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017 Jun 3; 389(10085): 2226-2237. Go to original source... Go to PubMed...
    5. Rawshani A, Rawshani A, Franzén et al. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2018; 379(7): 633-644. Go to original source... Go to PubMed...
    6. Yusuf S, Joseph P, Rangarajan S et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020 Mar 7; 395(10226): 795-808. Go to original source... Go to PubMed...
    7. Tuzcu EM, Kapadia SR, Tutar E et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation. 2001; 103(22): 2705-2710. Go to original source... Go to PubMed...
    8. Ahmadi A, Narula J. Primary and Secondary Prevention, or Subclinical and Clinical Atherosclerosis. JACC Cardiovasc Imaging. 2017 Apr;10(4):447-450. Go to original source... Go to PubMed...
    9. Nicholls SJ, Tuzcu EM, Sipahi I et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007 Feb 7;297(5):499-508. Go to original source... Go to PubMed...
    10. Emberson J, Whincup P, Morris R et al. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J. 2004 Mar; 25(6): 484-491. Go to original source... Go to PubMed...
    11. Ben-Shlomo Y, Spears M, Boustred C et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol. 2014 Feb 25; 63(7): 636-646. Go to original source... Go to PubMed...
    12. Ong KT, Delerme S, Pannier B et al. investigators. Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients. J Hypertens. 2011 Jun; 29(6): 1034-1042. Go to original source... Go to PubMed...
    13. Williams B, Lacy PS, Thom SM et al. CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006 Mar 7; 113(9): 1213-1225. Go to original source... Go to PubMed...
    14. Upala S, Wirunsawanya K, Jaruvongvanich V, Sanguankeo A. Effects of statin therapy on arterial stiffness: A systematic review and meta-analysis of randomized controlled trial. Int J Cardiol. 2017 Jan 15; 227: 338-341. Go to original source... Go to PubMed...
    15. Bruining N, de Winter S, Roelandt JR et al. EUROPA/PERSPECTIVE Investigators. Coronary calcium significantly affects quantitative analysis of coronary ultrasound: importance for atherosclerosis progression/regression studies. Coron Artery Dis. 2009 Sep; 20(6): 409-414. Go to original source... Go to PubMed...
    16. Klingbeil AU, Schneider M, Martus P et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003 Jul; 115(1): 41-46. Go to original source... Go to PubMed...
    17. Williams B, Mancia G, Spiering W, et al; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1; 39(33): 3021-3104. Go to original source... Go to PubMed...
    18. Dutta P, Courties G, Wei Y et al. Myocardial infarction accelerates atherosclerosis. Nature. 2012 Jul 19; 487(7407): 325-329. Go to original source... Go to PubMed...
    19. Gutierrez JA, Aday AW, Patel MR, Jones WS. Polyvascular Disease: Reappraisal of the Current Clinical Landscape. Circ Cardiovasc Interv. 2019 Dec; 12(12): e007385. Go to original source... Go to PubMed...
    20. Ferrari R. Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med. 2006 Mar 27; 166(6): 659-666. Go to original source... Go to PubMed...
    21. Bertrand ME, Ferrari R, Remme WJ et al. Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis. Am Heart J. 2015 Dec; 170(6): 1092-1098. Go to original source... Go to PubMed...
    22. Mach F, Baigent C, Catapano AL et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1; 41(1): 111-188. Go to original source... Go to PubMed...
    23. Kotseva K, De Backer G, De Bacquer D et al. EUROASPIRE Investigators*. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019 May; 26(8): 824-835. Go to original source... Go to PubMed...
    24. Khunti K, Danese MD, Kutikova L et al. Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe. JAMA Netw Open. 2018 Dec 7; 1(8): e185554. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.